Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates I-Mab Biopharma has announced plans to develop TJM2 (TJ003234) for the treatment of cytokine storm caused due to severe and critical Covid-19 infection.
Discovered by I-Mab, TJM2 is an antibody that neutralises human granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine associated with acute and chronic inflammation.
The development will begin after the US Food and Drug Administration (FDA) accepts the company’s investigational new drug (IND) application.
A study, initially performed in the US, will then launch in other profoundly affected countries. Cytokine storm leads to elevated circulating inflammatory cytokines levels.